With about 12% of the US population having now received their first dose of the vaccine, the broker believes hospitalisations in the US, Nanosonics' largest market, may have peaked.

The flipside is this should likely support a further recovery in ultrasound volumes in coming months as elective procedures pick up. Ahead of the company's earnings result, the broker retains Lighten, cutting its target to $5.60 from $5.65.

Sector: Health Care Equipment & Services.

Target price is $5.60.Current Price is $6.64. Difference: ($1.04) - (brackets indicate current price is over target). If NAN meets the Ord Minnett target it will return approximately -19% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena